Monday Lunch Live
Optimising radionuclide therapy for advanced prostate cancer
17 March 2025 (Video recording below)
Radionuclide therapy such as Lutetium-PSMA has transformed the management of advanced prostate cancer. However, not all patients respond and in those that do treatment resistance is inevitable. Finding ways to enhance the activity of radionuclide therapy is critical to delivering better outcomes for patients with advanced prostate cancer.
In this presentation, Prof Arun Azad will outline multiple strategies currently being investigated to optimise the efficacy of radionuclide therapy. This will include a detailed overview of the UpFrontPSMA trial, the first randomised clinical trial to show efficacy of Lutetium-PSMA in metastatic hormone-sensitive prostate cancer.
Chair
Prof Niall Corcoran
Head of Unit, Western Health, Research and Education Lead, GU Oncology, VCCC Alliance
Professor Corcoran is a urological surgeon and research scientist with an interest in the molecular drivers of lethal prostate cancer and novel treatments. He completed his studies at the University College of Dublin in 1998 and was awarded a PhD from the University of Melbourne in 2006. He is currently a professorial research fellow in the Department of Surgery.
Speaker
Prof Arun Azad
Medical Oncologist, Peter MacCallum Cancer Centre and the University of Melbourne
Prof Arun Azad is a medical oncologist focused on clinical and translational research in prostate cancer. He has past and ongoing leadership positions in numerous prostate cancer clinical trial steering committees serving as Co-Chair of the global phase III LIBERTAS and EvoPAR-Prostate01 trials.
His laboratory research involves pioneering work on the role of circulating tumour DNA in advanced prostate cancer. In addition to his strong research output, he holds key leadership roles including Translational Chair at ANZUP Cancer Trials Group and Urologic Oncology Chair at Clinical Oncology Society of Australia. He is also the Prostate Track Chair at the ESMO Congress 2024 and sits on the ESMO Clinical Practice Guidelines for Prostate Cancer.
Resource details
This course is brought to you by
